Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature

被引：2

作者：

Iaconi, Ala I. ^{[2
]}

Zimmerman, Marliese A. ^{[2
]}

Kulkarni, Amit S. ^{[2
]}

Balkrishnan, Rajesh ^{[1
]}

机构：

[1] Ohio State Univ, Coll Pharm & Publ Hlth, Columbus, OH 43210 USA

[2] Ohio State Univ, Coll Pharm & Publ Hlth, Columbus, OH 43210 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 02期

关键词：

clinical outcome; COMT inhibitor; DA; dopamine agonists; dyskinesia; economic outcome; fibrotic heart valve; HRQoL; levodopa; MAO inhibitor; Parkinson's disease; rasagiline; ropinirole; subcutaneous apomorphine; transdermal rotigotine; tremor;

D O I：

10.1517/14656566.9.2.163

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Parkinson's disease (PD) affects nearly 1 million Americans with a mean onset age of 60 years. Its progressive, neurodegenerative nature, causing motor complications and affecting mood, has a considerable impact on a patient's health-related quality of life. Pharmacologic therapies are the most widely utilized treatment. The broad range of drugs for treating PD warrants an assessment of each medication's health-related outcomes, which includes consideration of clinical, economic and patient-centered outcomes. This review seeks to explore the outcomes associated with drugs frequently appearing in the literature of the past 5 years and to comment on the direction of pharmacologic research and management of PD pharmacotherapy in the future.

引用

页码：163 / 174

页数：12

共 42 条

[1]

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease [J].

Antonini, Angelo ;

Poewe, Werner .

LANCET NEUROLOGY, 2007, 6 (09) :826-829

[2]

Rasagiline improves quality of life in patients with early Parkinson's disease [J].

Biglan, KM ;

Schwid, S ;

Eberly, S ;

Blindauer, K ;

Fahn, S ;

Goren, T ;

Kieburtz, K ;

Oakes, D ;

Plumb, S ;

Siderowf, A ;

Stern, M ;

Shoulson, I .

MOVEMENT DISORDERS, 2006, 21 (05) :616-623

[3]

New pharmacologic horizons in the treatment of Parkinson disease [J].

Bonuccelli, Ubaldo ;

Del Dotto, Paolo .

NEUROLOGY, 2006, 67 (07) :S30-S38

[4]

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease - Final results of a 5-year, double-blind, Levodopa-controlled study [J].

Bracco, F ;

Battaglia, A ;

Chouza, C ;

Dupont, E ;

Gershanik, O ;

Masso, JFM ;

Montastruc, JL .

CNS DRUGS, 2004, 18 (11) :733-746

[5]

The Parkinson-control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease [J].

Castro-Caldas, A ;

Delwaide, P ;

Jost, W ;

Merello, M ;

Williams, A ;

Lamberti, P ;

Aguilar, M ;

Del Signore, S ;

Cesaro, P .

MOVEMENT DISORDERS, 2006, 21 (04) :500-509

[6]

The economic evaluation of pharmacotherapies for Parkinson's disease [J].

Coyle, D ;

Barbeau, A ;

Guttman, M ;

Baladi, JF .

PARKINSONISM & RELATED DISORDERS, 2003, 9 (05) :301-307

[7]

Amantadine reduces the duration of levodopa-induced dyskinesia:: A randomized, double-blind, placebo-controlled study [J].

da Silva-Júnior, FP ;

Braga-Neto, P ;

Monte, FS ;

de Bruin, VMS .

PARKINSONISM & RELATED DISORDERS, 2005, 11 (07) :449-452

[8]

A review of the health-related quality of life and economic impact of Parkinson's disease [J].

Dowding, Clare H. ;

Shenton, Claire L. ;

Salek, Sam S. .

DRUGS & AGING, 2006, 23 (09) :693-721

[9]

Does levodopa slow or hasten the rate of progression of Parkinson's disease? [J].

Fahn, S .

JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 4) :37-42

[10]

Present and future approaches to Parkinson disease - From molecular insights to new therapeutic avenues [J].

Fariello, Ruggero G. ;

Lieberman, Abraham .

NEUROLOGY, 2006, 67 (07) :S1-S4

← 1 2 3 4 5 →